tradingkey.logo

Aptar beats Q4 revenue, profit estimates; announces $600 mln buyback

ReutersFeb 5, 2026 10:09 PM


Overview

  • Drug delivery tech firm's Q4 revenue grew 14%, beating analyst expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company announced new $600 mln share repurchase authorization


Outlook

  • Aptar expects Q1 2026 adjusted EPS between $1.13 and $1.21

  • Company anticipates strong Pharma growth outside emergency medicine

  • Aptar forecasts 2026 capital investments of $260 mln to $280 mln


Result Drivers

  • PHARMA GROWTH - Driven by strong demand for elastomeric components and systemic nasal drug delivery technologies

  • BEAUTY DEMAND - Double-digit growth in Beauty segment due to increased demand for dispensing technologies

  • PROFITABILITY IMPACT - Less favorable product mix and higher production costs affected overall profitability


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$963 mln

$882.21 mln (6 Analysts)

Q4 Adjusted EPS

Beat

$1.25

$1.23 (7 Analysts)

Q4 EPS

$1.13

Q4 Net Income

$74.3 mln

Press Release: ID:nBw6JcRQka

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI